Trametinib: all 183 studies that test it
Page 2 of 2. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.
- A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerTerminatedNCT04294160Phase 1
- Trametinib in the Treatment of Complicated Extracranial Arterial Venous MalformationCompletedNCT04258046Phase 2
- Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid CancerActive, not recruitingNCT04238624Phase 2
- A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)Active, not recruitingNCT04111458Phase 1
- TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type MelanomaCompletedNCT04059224Phase 2
- Pediatric Long-Term Follow-up and Rollover StudyActive, not recruitingNCT03975829Phase 4
- Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid CancerSuspendedNCT03975231Phase 1
- Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant MelanomaWithdrawnNCT03972046Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic CancerTerminatedNCT03825289Phase 1
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
- Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant MelanomaStatus unknownNCT03754179Phase 1/2
- Treatment of NF1-related Plexiform Neurofibroma With TrametinibActive, not recruitingNCT03741101Phase 2
- Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-typeCompletedNCT03714958Phase 1
- Dabrafenib + Trametinib + PDR001 In Colorectal CancerStatus unknownNCT03668431Phase 2
- EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR MutationsCompletedNCT03516214Phase 1
- Study of Trametinib + Ceritinib in Patients With Unresectable MelanomaCompletedNCT03501368Phase 1
- SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain TumorsCompletedNCT03434262Phase 1
- Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.Active, not recruitingNCT03363217Phase 2
- Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic MelanomaCompletedNCT03352947Phase 2
- Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by SurgeryCompletedNCT03317119Phase 1
- A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid TumorsWithdrawnNCT03266159Phase 2
- Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally AdvancedActive, not recruitingNCT03225664Phase 1/2
- A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT03091257Phase 1
- Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced MelanomaStatus unknownNCT03088176Phase 1
- Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03087448Phase 1
- Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal CancerActive, not recruitingNCT03087071Phase 2
- Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid CancerActive, not recruitingNCT03085056Early Phase 1
- Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationTerminatedNCT03065387Phase 1
- Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid TumoursWithdrawnNCT02939846Phase 1
- A Clinical Trial of Patients With MelanomaWithdrawnNCT02915666Phase 1
- Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaActive, not recruitingNCT02910700Phase 2
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
- Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate CancerActive, not recruitingNCT02881242Phase 2
- BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic MelanomaCompletedNCT02872259Phase 1/2
- A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid TumorsCompletedNCT02705963Phase 1
- Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid TumorsTerminatedNCT02703571Phase 1
- Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLCWithdrawnNCT02672358Phase 2
- Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic MelanomaCompletedNCT02645149Phase 2
- Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02580708Phase 1/2
- Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibTerminatedNCT02538627Phase 1
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With MelanomaWithdrawnNCT02447939Phase 1
- A Study of GSK2256098 and Trametinib in Advanced Pancreatic CancerCompletedNCT02428270Phase 2
- Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced MelanomaTerminatedNCT02410863Phase 2
- A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal CancerCompletedNCT02399943Phase 2
- Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or TrametinibWithdrawnNCT02357732Phase 1
- SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)WithdrawnNCT02342600Phase 2
- Study of Trametinib and Nab-paclitaxel in Patients With MelanomaWithdrawnNCT02300935Phase 1
- A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid TumorsWithdrawnNCT02292732Phase 1
- Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular CancerCompletedNCT02292173Phase 1
- Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in PhaseTerminatedNCT02258607Phase 1
- Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationActive, not recruitingNCT02231775Phase 2
- Lapatinib Plus Trametinib in KRAS Mutant NSCLCCompletedNCT02230553Phase 1/2
- Study of Dabrafenib, Trametinib and Metformin for Melanoma PatientsWithdrawnNCT02143050Phase 1/2
- UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered TrametinibWithdrawnNCT02140840Phase 2
- A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type MelanomaCompletedNCT02138292Phase 1
- Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic DysfunctionCompletedNCT02070549Phase 1
- A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid TumorsCompletedNCT02065063Phase 1
- Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerActive, not recruitingNCT01990196Phase 2
- Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive MelanomaCompletedNCT01972347Phase 2
- Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01940809Phase 1
- Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung CancerWithdrawnNCT01938456Phase 1
- A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid TumorsCompletedNCT01938443Phase 1
- Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryTerminatedNCT01912625Phase 1
- Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable MelanomaCompletedNCT01767454Phase 1
- Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal CancerCompletedNCT01740648Phase 1
- A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212CompletedNCT01658553Phase 1
- Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) FormulationCompletedNCT01647659Phase 1
- A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor CancersCompletedNCT01476137Phase 1
- Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212CompletedNCT01467310Early Phase 1
- Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and CholangiocarcinomaCompletedNCT01438554Phase 1
- Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid TumorsCompletedNCT01428427Phase 1
- Absolute Bioavialability of GSK1120212CompletedNCT01416337Phase 1
- Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212CompletedNCT01387204Phase 1
- GSK1120212 Food-effect StudyCompletedNCT01371487Phase 1
- Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal MelanomaWithdrawnNCT01328106Phase 2
- Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid TumorsCompletedNCT01324258Phase 1
- Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.TerminatedNCT01248858Phase 1
- A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor PatientsCompletedNCT01155453Phase 1
- Safety, Pharmacokinetics (PK) of AKT and MEK CombinationCompletedNCT01138085Phase 1
- A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer SubjectsCompletedNCT00955773Phase 1
- Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or LymphomaCompletedNCT00687622Phase 1